Skip to content

HOME
About EFB
Pipeline
News
Investors
- SEC Filings
Contact Us
Language
- 中文
- 日本語

Everfront Biotech Inc.- Rising Star in Pharmaceutical Innovation

EFB is committed to fulfilling unmet medical needs

by developing orphan drugs to treat the world’s most lethal diseases including high grade glioma and pancreatic cancer

Brain Tumor (Glioblastoma, GBM) and Pancreatic Cancer (PC)

EFB'S Mission

EFB’s Mission

EFB is committed to fulfilling unmet medical needs

Rising Star in Pharmaceutical Innovation

Rising Star in Pharmaceutical Innovation

EFB is committed to fulfilling unmet medical needs by developing orphan drugs to treat the world’s most lethal diseases.

Cerebraca® Wafer

Curing Rare Cancer

Curing Rare Cancers

Including
Glioblastoma (GBM) and
Pancreatic cancer (PC)

EF-009 | PC Treatment

PRODUCT HIGHLIGHTS of Cerebraca® Wafer

A Biodegradable Implant Targeting GBM with One-month Sustained Drug Release

Latest News

Everfront Biotech to Unveil Breakthrough Clinical Trial Results for Cerebraca® Wafer in Brain Cancer Treatment at 2024 Taiwan Healthcare+ Expo

Everfront Biotech to Unveil Breakthrough Clinical Trial Results for Cerebraca® Wafer in Brain Cancer Treatment at 2024 Taiwan Healthcare+ Expo

Nov 28, 2024

Everfront Biotech at BIO 2024: Competing in the Taiwan Smart Health GALA with 22 Startups

Everfront Biotech at BIO 2024: Competing in the Taiwan Smart Health GALA with 22 Startups

June 3, 2024

Everfront Biotech's Investigational product, Cerebraca® Wafer, has achieved significant progress in Phase I clinical trials for the treatment of malignant brain tumors, and has been invited to speak at the Asian Congress of Neurological Surgeons (ACNS).

Everfront Biotech's Investigational product, Cerebraca® Wafer, has achieved significant progress in Phase I clinical trials for the treatment of malignant brain tumors, and has been invited to speak at the Asian Congress of Neurological Surgeons (ACNS).

June 9, 2022

Everfront Biotech's Cerebraca® Wafer has Completed the Phase I - Safety Evaluation for the Treatment of Glioblastoma Multiforme, and has Initiated the Phase IIa - Efficacy Evaluation

Everfront Biotech's Cerebraca® Wafer has Completed the Phase I - Safety Evaluation for the Treatment of Glioblastoma Multiforme, and has Initiated the Phase IIa - Efficacy Evaluation

April 9, 2022

Explore Everfront Biotech

About Everfront

Scientific Publications

We want to hear from you.

Development Pipeline

Pepline - EF-001

Pepline - EF-009

Pepline - HK-001

Pepline - EF-031

Everfront Biotech Inc. is committed to fulfilling unmet medical needs by developing orphan drugs to treat the world’s most lethal diseases.

Privacy policy

TEL: +886-2-27563796

Email:

efbiotech@efbiotech.com

Copyright © 2025 Everfront Biotech. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.